Page 40 - Read Online
P. 40

Page 10 of 12             Armengol et al. Hepatoma Res 2021;7:50  https://dx.doi.org/10.20517/2394-5079.2021.19

               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2021.


               REFERENCES
               1.       Kehm RD, Osypuk TL, Poynter JN, Vock DM, Spector LG. Do pregnancy characteristics contribute to rising childhood cancer
                   incidence rates in the United States? Pediatr Blood Cancer 2018:65.  DOI  PubMed  PMC
               2.       Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma 2017;4:15-21.
                   DOI  PubMed  PMC
               3.       Rikhi RR, Spady KK, Hoffman RI, Bateman MS, Bateman M, Howard LE. Hepatoblastoma: a need for cell lines and tissue banks to
                   develop targeted drug therapies. Front Pediatr 2016;4:22.  DOI  PubMed  PMC
               4.       Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6.  DOI  PubMed
               5.       Czauderna P. Adult type vs. Childhood hepatocellular carcinoma--are they the same or different lesions? Med Pediatr Oncol
                   2002;39:519-23.  DOI  PubMed
               6.       Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the
                   International Society of Pediatric Oncology group. J Clin Oncol 2002;20:2798-804.  DOI  PubMed
               7.       Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Hepatocellular carcinoma in children and adolescents: results from the
                   Pediatric Oncology Group and the Children's Cancer Group intergroup study. J Clin Oncol 2002;20:2789-97.  DOI  PubMed
               8.       Lopez-Terrada D, Alaggio R, de Davila MT, et al. Towards an international pediatric liver tumor consensus classification: proceedings
                   of the Los Angeles COG liver tumors symposium. Mod Pathol 2014;27:472-91.  DOI  PubMed
               9.       Prokurat A, Kluge P, Kosciesza A, Perek D, Kappeler A, Zimmermann A. Transitional liver cell tumors (TLCT) in older children and
                   adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol 2002;39:510-8.  DOI  PubMed
               10.      Zimmermann A. The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. Eur J Cancer 2005;41:1503-14.
                   DOI  PubMed
               11.      Cairo S, Armengol C, De Reynies A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in
                   aggressive childhood liver cancer. Cancer Cell 2008;14:471-84.  DOI  PubMed
               12.      Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated
                   degradation targeting box of the beta-catenin gene. Cancer Res 1999;59:269-73.  PubMed
               13.      Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA. Activation of beta-catenin in epithelial and mesenchymal
                   hepatoblastomas. Oncogene 2000;19:498-504.  DOI  PubMed
               14.      Eichenmüller M, Trippel F, Kreuder M, et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J
                   Hepatol 2014;61:1312-20.  DOI  PubMed
               15.      Sekiguchi M, Seki M, Kawai T, et al. Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel
                   druggable targets. NPJ Precis Oncol 2020;4:20.  DOI  PubMed  PMC
               16.      Sumazin P, Chen Y, Trevino LR, et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups.
                   Hepatology 2017;65:104-21.  DOI  PubMed
               17.      Hirschman BA, Pollock BH, Tomlinson GE. The spectrum of APC mutations in children with hepatoblastoma from familial
                   adenomatous polyposis kindreds. J Pediatr 2005;147:263-6.  DOI  PubMed
               18.      Koch A, Weber N, Waha A, et al. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas. J Pathol
                   2004;204:546-54.  DOI  PubMed
               19.      Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and
                   hepatoblastomas. Oncogene 2002;21:4863-71.  DOI  PubMed
               20.      Trobaugh-Lotrario AD, Venkatramani R, Feusner JH. Hepatoblastoma in children with Beckwith-Wiedemann syndrome: does it
                   warrant different treatment? J Pediatr Hematol Oncol 2014;36:369-73.  DOI  PubMed
               21.      Ansell P, Mitchell CD, Roman E, Simpson J, Birch JM, Eden TO. Relationships between perinatal and maternal characteristics and
                   hepatoblastoma: a report from the UKCCS. Eur J Cancer 2005;41:741-8.  DOI  PubMed
               22.      McLaughlin CC, Baptiste MS, Schymura MJ, Nasca PC, Zdeb MS. Maternal and infant birth characteristics and hepatoblastoma. Am J
                   Epidemiol 2006;163:818-28.  DOI  PubMed
               23.      Grobner SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across childhood cancers. Nature 2018;555:321-
                   7.  DOI  PubMed
   35   36   37   38   39   40   41   42   43   44   45